
January 29, 2025
BlinkLab Limited (ASX:BB1) (“BlinkLab”, or the “Company”) an innovative digital healthcare company leveraging smartphones, computer vision, Artificial Intelligence (“AI”), and Machine Learning (“ML”) to diagnose neurodevelopmental conditions such as autism and ADHD, is pleased to release its Appendix 4C and Quarterly Activity Report for the period ended 31 December 2024 (the “Quarter”).
Highlights
- BlinkLab initiated its FDA registrational study, which aims to revolutionise the diagnostics and care for autism, making it more accessible and reliable.
- The initial phase will recruit up to 100 participants (children aged between 2-11 years old), with the main study recruiting up to 1,000 subjects.
- Four clinical sites have been selected, with six additional sites to be added; the sites are spread across the US to ensure diversity of the population.
- Final results are expected by the end of CY 2025 and will be used for the 510(k) Food and Drug Administration (“FDA”) approval.
- BlinkLab received positive feedback from a Pre-Submission meeting with the US Federal Drug Administration (“FDA”) regarding the regulatory pathway for BlinkLab Dx 1 diagnostic app.
- Final results from the pivotal autism study (announced in November of 2024) bolster confidence that BlinkLab Dx 1 will surpass the accuracy parameters that are required for regulatory approval in the upcoming FDA registration trial.
- BlinkLab and Monash University have partnered on the large-scale Monash Autism-ADHD Genetics and Neurodevelopment (“MAGNET”) study, which aims to conduct deep phenotyping in children on the autism spectrum, with ADHD, or both. The study will also work towards further improvements to BlinkLab’s Machine Learning (“ML”) algorithm to better distinguish between autism- and ADHD-specific clinical features.
- As at 31 December 2024, the Company had a cash balance of A$4.4 million.
Following the positive outcome from the recent FDA pre-submission meeting, as well as positive final data from the pivotal preliminary study (ASX Announcement 19 November 2024), BlinkLab is confident in the success of its registrational study, as well as the subsequent 510(k) regulatory approval for our first diagnostic tool for autism, called “Blinklab Dx 1”.
US FDA Registrational Study in Autism Now Underway
The FDA registrational study program will consist of a pilot study, followed by the primary study. The pilot study will recruit up to 100 participants (children aged between 2-11 years) and will continue into a registrational study, which will be conducted with up to 1,000 subjects across ten clinical sites in the US. The pilot study will be used to train the investigators and personnel at clinical sites, as well as to test the procedures of subject screening and data collection. These steps are part of BlinkLab’s considered strategy for mitigating risk leading up to the main FDA study and are aimed at ensuring the highest quality of data and diagnostic accuracy of the BlinkLab tests.
Click here for the full ASX Release
This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
BB1:AU
The Conversation (0)
01 May
Successful Placement of A$7.66M to Underpin Growth Strategy
BlinkLab Limited (BB1:AU) has announced Successful Placement of A$7.66M to Underpin Growth StrategyDownload the PDF here. Keep Reading...
29 April
Trading Halt
BlinkLab Limited (BB1:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
27 April
Quarterly Activities/Appendix 4C Cash Flow Report
BlinkLab Limited (BB1:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
31 March
BlinkLab Surpasses Key Milestone in Pivotal U.S. Trial
BlinkLab Limited (BB1:AU) has announced BlinkLab Surpasses Key Milestone in Pivotal U.S. TrialDownload the PDF here. Keep Reading...
30 March
Trading Halt
BlinkLab Limited (BB1:AU) has announced Trading HaltDownload the PDF here. Keep Reading...
26 September
Tech Weekly: Tech Stocks React to Fed, AI News and Geopolitical Tensions
This week’s market action reflected renewed caution amid evolving signals from the US Federal Reserve, with tech stocks facing pressure from shifting interest rate expectations and renewed overvaluation concerns. Artificial intelligence (AI) heavyweight NVIDIA (NASDAQ:NVDA) announced a US$100... Keep Reading...
26 September
Syntheia Signs Definitive Agreement for Call Center Acquisition
Syntheia Corp. (CSE: SYAI) ("Syntheia" or the "Company") (syntheia.ai), today announced that it has entered into an amended and restated agreement dated September 25, 2025 (the "Restated Agreement") with Call Center Guys Inc. ("CCG"), to amend and restate the terms of an asset purchase agreement... Keep Reading...
23 September
NVIDIA Commits US$100 Billion to OpenAI in Landmark AI Infrastructure Push
Semiconductor giant NVIDIA (NASDAQ:NVDA) plans to invest up to US$100 billion in OpenAI to build what executives are calling the largest artificial intelligence (AI) infrastructure project in history.The companies said on Monday (September 22) that OpenAI will deploy NVIDIA's systems on a scale... Keep Reading...
22 September
How to Invest in OpenAI's ChatGPT
OpenAI’s ChatGPT is one of the latest technological breakthroughs in the artificial intelligence space. But what is ChatGPT, and can you invest in OpenAI?This emerging technology is representative of a niche subsector of the AI industry known as generative AI — systems that can generate text,... Keep Reading...
19 September
Tech Weekly: Semiconductor Stocks Rally on Fed Rate Cut and Strategic Deal
The US Federal Reserve lowered its key interest rate for the first time in 2025 this week, while the Bank of Canada resumed cutting after pausing in March, providing a boost to growth-oriented sectors.Tech stocks, particularly semiconductor and artificial intelligence (AI) companies, responded... Keep Reading...
16 September
NVIDIA Facing Weak Demand for New Chip as Chinese Firms Turn to Homegrown Silicon
NVIDIA's (NASDAQ:NVDA) new RTX6000D chip, built to comply with US export curbs, is seeing little demand from major Chinese firms, sources familiar with the matter told Reuters this week. Tests showed it lags the banned RTX5090, which remains widely available through gray market channels at less... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00